Revised 7/20/06

PGY4 Advances in Psychiatry Seminar

September 2006 – February 2007
Thursdays 2:45 – 4:00 p.m.
Conference Room LG066

Date 09/07/06
Presenter Dr. Andrew Winokur
Topic Introduction/Social Imperatives of Biomedical Research
Reading
1. Eisenberg, Leon, “The Social Imperatives of Medical Research”, Science, 16 Dec. 1977, Vol. 198, Number
4322.

Dates 09/14/06
Presenter Dr. Leighton Huey
Topic Vagal Nerve Stimulation I
Reading
1. George, Mark; Marangell, Lauren; Nahas, Ziad; Ballenger, James, “Vagus Nerve Stimulation: A Potential
Therapy for Resistant Depression?”, The Psychiatric Clinics of North America, Vol. 23, No. 4, December
2000.
2. George, Mark; Sackeim, Harold; Rush, John; Marangell, Lauren; Nahas, Ziad, Husain, Mustafa; Lisanby,
Sarah; Burt, Tal; Goldman, Juliet; Ballenger, James, “Vagus Nerve Stimulation: A New Tool for Brain
Research and Therapy”, 2000 Society of Biological Psychiatry

Date 09/21/06
Presenter Dr. Leighton Huey
Topic Vagal Nerve Stimulation II
Readings Same as last week’s seminar

Date 09/28/06
Presenter Dr. Jonathan Covault
Topic Contributions of Genetics to Treatment of Mental Disorders I
Reading
1. Drazinic CM, Ercan-Sencicek, Gault LM, Hisama FM, Qumsiyeh MB, Nowak NJ, Cubells JF, State MW,
“Rapid Array-Based Genomic Characterization of a Subtle Structural Abnormality: A Patient with Psychosis
and der (18)t(5;18)(P14.1;p11.23). American Journal of Medical Genetics 134A:282-289 (2005). Copyright
Wiley-Liss, Inc.

Page 1
 Revised 7/20/06
2. Zubenko GS, Hughes HB, Stiffler JS, “D10S1423 identifies a susceptibility locus for Alzheimer’s disease in a
prospective, longitudinal, double-blind study of asymptomatic individuals”, Molecular Psychiatry (2001), 6,
413-419.
3. Tang, Minig-Xin; Yaakov, Stern; Marder, Karen; Bell, Karen, Gurland, Barry; Lantigua, Rafael; Andrews,
Howard; Feng, Lin; Tycko, Benjamin; Mayeux, Richard, “The APOE-4 Allele and the Risk of Alzheimer
Disease Among African Americans, Whites and Hispanics”, JAMA, March 11, 1998, Vol. 279, No. 10, 751-
787.
4. Jordan, Barry; Relkin, Normal; Ravdin, Lisa; Jacobs, Alan; Bennett, Alexandre; Gandy, Sam, “Apolipoprotein
E 4 Associated With Chronic Traumatic Brain Injury in Boxing”, JAMA, July 9, 1997, Vol. 278, No. 2, 136-
140.
5. Roses, Allen, “Pharmacogenetics and the Practice of Medicine”, Nature, Vol. 405, June 15, 2000, 857-865.
6. Kukull, Walter; Martin, George, “APOE Polymorphisms and Late-Onset Alzeheimer Disease; The Importance
of Ethnicity”, JAMA, March 11, 1998, Vol. 279, No. 10, 788-790.

Date 10/5/06
Presenter Dr. Jonathan Covault
Topic Contributions of Genetics to Treatment of Mental Disorders II
Readings
1. Turecki, G; Grof, P; Grof, E, D’Souza, V; Lebuis, L; Marineau, C; Cavazzoni, P; Duffy, A; Betard, C;
Zvolsky, P; Robertson, C; Brewer, C; Hudson, TJ; Rouleau, GA; Alda, M, “Mapping susceptibility genes for
bipolar disorder: a pharmacogenetic approach based on excellent response to lithium, Molecular Psychiatry
(2001) 6, 570-578.
2. Serretti, A; Zanardi, R; Rossini, D; Cusin, C; Lilli, R; Smeraldi, E, “Influence of tryptophan hydroxylase and
serotonin transporter genes on fluvoxamine antidepressant activity, Molecular Psychiatry (2001), 6, 586-592.
3. Letters to the Editors, “Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism
Within the Promoter of the Serotonin Transporter Gene”, Journal of Clinical Psychopharmacology, Vol.
20/No. 1, February 2000, 105-107.
4. Arias, Barbara; Catalan Rosa; Gasto, Cristobal; Gutierrez, Blanca; Fananas, Lourdes, “5-HTTLPR
Polymorphism of the Serotonin Transporter Gene Predicts Non-Remission in Major Depression Patients
Treated With Citalopram in a 12-Weeks Follow Up Study”, Journal of Clinical Psychopharmacology, Vol.
23/No. 6, December 2004, 563-567.
5. Caspi, Avshalom; Sugden, Karen; Moffitt, Terrie; Taylor, Alan; Craig, Ian; Harrington, HonaLee; McClay,
Joseph; Mill, Jonathan; Martin, Judy; Braithwaite, Antony; Poulton, Richie, “Influence of Life Stress on
Depression: Moderation by a Polymorphism in the 5-HTT Gene”, Science, Vol. 301, July 18, 2003, 386-389.

Page 2
 Revised 7/20/06
6. Herman, Aryeh; Philbeck, John; Vasilopoulos, Nicholas; Depetrillo, Paolo, “Serotonin Transporter Promoter
Polymorphism and Differences in Alcohol Consumption Behaviour in a College Student Population”, Alcohol
& Alcoholism, Vol. 38/No. 5, (2003), 446-449.

Date 10/12/06
Presenter Dr. Howard Tennen
Topic Depression, Positive Illusions, and Health: Cardiovascular Disease
1. Outline from Dr. Tennen on Positive Illusions, Psychological Well Being and Health
2. Frasure-Smith N, Lesperance F. Reflections on Depression as a Cardiac Risk Factor. Psychosomatic Medicine
67, Supplement 1:pp. S19-S25 (2005), Copyright 2005 by the American Psychosomatic Society.
3. Giltay EJ, Kamphuis MH, Kalmijn S, Zitman FG, Kromhout D. Dispositional Optimism and the Risk of
Cardiovascular Death. Arch Intern Med/Vol. 166, Feb 27, 2006, Copyrighted 2006 American Medical
Association.
4. Afflect G, Tennen, H, Croog S, Levine S. Causal Attribution, Perceived Benefits, and Morbidity After a Heart
Attack: An 8-Year Study. Journal of Consulting and Clinical Psychology, 1987, Vol. 55, No. 1:29-35.
Copyright 1987 by the American Psychological Association, Inc.
5. Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and
morbidity – A review of potential mechanisms. Journal of Psychosomatic Research 53 (2002) 897-902.

Date 10/19/06
No Seminar – Faculty Retreat

Date 10/26/06
Presenter Dr. Lisa Conti
Topic Physiopathology of Depression
Reading
1. Barden, Nicholas; “Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of
depression”, J Psychiatry Neurosci 2004; 29 (3), 185-193.

Date 11/2/06
Presenter Dr. Victor Hesselbrock
Topic Animal Models of Psychiatric Disorders
Reading
1. Hitzemann, Robert, “Animal Models of Psychiatric Disorders and Their Relevance to Alcoholism”, Alcohol
Research & Health 2000, Vol. 24, No. 3, 149-158.
2. Grahame, Nicholas, “Selected Lines and Inbred Strains”, Alcohol Research & Health 2000, Vol. 24, No. 3, 159-
163.

Date 11/9/06

Page 3
 Revised 7/20/06
Presenter Dr. Victor Hesselbrock
Topic The Genetics of Alcoholism
Readings
1. Hesselbrock, Victor; Foroud, Tatiana; Edenberg, Howard; Nurnberger, John; Reich, Theodore; Rice,
John, “Genetics and Alcoholism: The COGA Project

Date 11/16/06
Presenter Drs. Julian Ford
Topic Biology of PTSD
Readings
1. Outline from Dr. Ford on Biology of PTSD
2. Yehuda, Rachel, “Biology of Posttraumatic Stress Disorder”, J Clinical Psychiatry 2000; 61 (suppl &), 14-21.

Date 11/23/06
No Seminar – Thanksgiving Day

Date 11/30/06
Presenter Dr. Julian Ford
Topic Implications of Psychobiology for Treatment of Complex PTSD
Reading
1. Outline from Dr. Ford on Biology of PTSD
2. Self Regulation/Neurogiology (PowerPoint)
3. Ford JD, Exposure to Early Life Traumatic Stress and Psychobiological Self-Regulation
4. Ford JD, Courtois CA, Steel K, van der Hart O, Nijenhuis ERS, “Treatment of Complex Posttraumatic Self-
Dysregulation
5. Morgan, Charles; Krystal, John; Southwick, Steven, “Toward Early Pharmacological Posttraumatic Stress
Intervention,” Society of Biological Psychiatry 2003; 53, 834-843.

Date 12/07/06
Presenter Dr. Andrew Winokur
Topic Advances in Psychopharmacology I

Page 4
 Revised 7/20/06
Readings
1. Outline from Dr. Winokur on Drug Development-Controlled Clinical Trials
2. Cole, Jonathan, “The Future of Controlled Clinical Trials”, Psychopharmacology Bulletin, Vol. 27, No. 1,
1991, 3-8.
3. Khan, Arif; Warner, Heather; Brown, Walter, “Symptom Reduction and Suicide Risk in Patients Treated with
Placebo in Antidepressant Clinical Trials: An Analysis of the Food and Drug Administration, Archives of
General Psychiatry, Vol. 57(4), April 2000, 311-317.
4. Khan A, Khan SR, Leventhan RM, Brown WA, “Symptom Reduction and Suicide Risk Among Patients
Treated with Placebo in Antipsychotic Clinical Trials: An Analysis of the Food and Drug Administration
Database, Am Psychiatry 158:9, September 2001, 1449-1454.
5. Kahn, Arif; Khan, Shirin; Walens, Gary; Kolts, Russell; Giller, Earl, “Frequency of Positive Studies Among
Fixed and Flexible Dose Antidepressant Clinical Trials; An Analysis of the Food and Drug Administration
Summary Basis of Approval Reports”, Neuropsychopharmacology, Vol. 28, (2003), 552-557.

Date: 12/14/06
Presenter Dr. Andrew Winokur
Topic Advances in Psychopharmacology II
Readings
1. Outline from Dr. Winokur on Advances in Psychopharmacology
2. Belanoff, Joseph; Flores, Benjamin; Kalezhan, Michelle; Sund, Brenda; Schatzberg, Alan, “Rapid Reversal of
Psychotic Depression Using Mifepristone”, Journal of Clinical Psychopharmacology, Vol. 21(5), October
2001, 516-521.
3. Gary, KA, Sevarino KA, Yarbrough G, Prange AJ, and Winokur A, “The thyrotropin-releasing hormone
(TRH) hypothesis of homeostasic regulation: Implications for TRH-based therapeutics. J Pharmacol Exptl
Therap 305:410-416, 2003.

Date 12/21/06
No Seminar – Holiday Break

Date: 12/28/06
No Seminar – Holiday Break

Date: 01/04/07
Presenter Dr. Henry Kranzler
Topic New Models in the Treatment of Alcohol Dependence I
Readings

Page 5
 Revised 7/20/06
1. Outline from Dr. Kranzler on Pharmacotherapy of Alcoholism
2. Littleton JM, DeWitte P, Litten R, Gessa GL, et al. Challenges to medications development in treating alcohol
dependence: An internal perspective. Alcohol & Alcoholism 2004, 9 (4) 271-275.
3. Garbutt JC, Kranzler HR, O’Malley SS, Gastfriend DF, Pettinatti HM, Silverman BL, Loewy JW, Ehrich EW.
Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized
Controlled Trial. JAMA, April 6, 2005, Vol. 293, No. 13, pp. 1617-1625.
4. Johnson BA, Ait-Daoud Nassima, Bowden CL, et al. Oral Topiramate for treatment of alcohol dependence: a
randomized controlled trial. The Lancet, May 17, 2003, 361: 1677-85.

Date: 01/11/07
Presenter Dr. Henry Kranzler
Topic New Models in the Treatment of Alcohol Dependence II
Readings Same readings as last week

Date: 01/18/07
Presenter Dr. Nicholas DeMartinis
Topic Anxiety Disorders I
Readings
1. Gross, Cornelius; Zhuang, Ziaoxi; Stark, Kimberly; Ramboz, Sylvia; Oosting, Ronald; Kirby, Lynn; Santarelli,
Luca; Beck, Sheryl; Hen, Renee, “Serotonin 1A receptor acts during development to establish normal anxiety-
like behavior in the adult”, Nature, Vol. 416, 28 March 2002.
2. Cowley, Deborah; Ha, Eileen; Roy-Byrne, Peter, “Determinants of Pharmacologic Treatment Failure in Panic
Disorder”, J Clin Psychiatry 58:12, December 1997.
3. PowerPoint Slides from Dr. DeMartinis on Treatment Resistant Anxiety: Issues and Options.

Date: 01/25/07
Presenter Dr. Nicholas DeMartinis
Topic Anxiety Disorders II
Readings Same as last week

Date: 02/01/07
Presenter Dr. Kaloyan Tanev
Topic Neuroimaging, PTSD, and the Hippocampus
Readings
1. Bremner JD, Vythilingam M, Vermetten E, et al. MRI and PET study of deficits in the hippocampal structure
and function in women with childhood sexual abuse and posttraumatic stress disorder. Am J Psychiatry 2003,
160:924-932

Page 6
 Revised 7/20/06
2. Bonne O, Brandes D, Gilboa A, et al. Longitudinal MRI study of hippocampal volume in trauma survivors
with PTSD. Am J Psychiatry 2001, 158(8), 1248-1251
3. Gilbertson MW, Shenton ME, Ciszewski A, et al. Smaller Hippocampal volume predicts pathologic
vulnerability to psychological trauma. Nature Neuroscience 2002, 5(11): 1242-1247.

Date: 02/08/07
Presenter Dr. Kaloyan Tanev
Topic REM Sleep
Readings
1. Parkinson’s, and Lewy Body Dementia ARTICLES: McKeith IG, Galasco D, Kosaka K, et al. Consensus
guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the
consortium on DLB international workshop. Neurology, 47(5), Nov 1996, 1113-1124.
2. Ferman TJ, Boeve BF, Smith GE, et al. REM sleep behavior disorder and dementia: Cognitive differences
when compared with AD. Neurology, 52(5), March 1999, 951-957
3. Arnulf I, Bonnet A, Damier P, et al. Hallucinations, REM Sleep and Parkinson’s Disease: a medical
hypothesis. Neurology, 55(2), July 2000, 281-288.
4. Lunesta General Summary Letter, 1-24.
5. Rosenberg, Russell; Caron, Judy; Roth, Thomas; Amato, David, “An assessment of the efficacy and safety of
eszopiclone in the treatment of transient insomnia in healthy adults”, Sleep Medicine, Vol. 6 (2005), 15-22.
6. Krystal, Andrew; Walsh, James; Laska, Eugene; Caron, Judy; Amato, David; Wessel, Thomas; Roth, Thomas,
“Sustained Efficacy of Eszopiclone Over 6 Months of Nightly Treatment: Results of a Randomized, Double-
Blind, Placebo-Controlled Study in Adults with Chronic Insomnia”, Sleep, Vol. 26/No. 7, (2003), 793-799.

Date: 02/15/07
Presenter Dr. Virginia Hofmann
Topic Deceit
Readings Articles to be distributed at seminar

Page 7